Erasca, Candle, Xencor drop as BofA downgrades on lack of near-term catalysts
Source: SeekingAlpha
2025-09-03 15:14:48 ET
More on Erasca, Xencor, etc.
- Candel Therapeutics announces $15M in direct offering
- Incyte granted FDA label expansion for lymphoma therapy Monjuvi
- Seeking Alpha’s Quant Rating on Erasca
- Historical earnings data for Erasca
- Financial information for Erasca
Read the full article on Seeking Alpha
For further details see:
Erasca, Candle, Xencor drop as BofA downgrades on lack of near-term catalysts
Candel Therapeutics Inc.
NASDAQ: CADL
CADL Trading
-4.43% G/L:
$4.745 Last:
703,959 Volume:
$5.04 Open:
CADL Latest News
March 12, 2026 08:05:00 am
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
March 09, 2026 08:05:00 am
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
February 24, 2026 08:05:00 am
Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston
CADL Stock Data
$316,763,208
45,785,185
2.24%
22
N/A
Biotechnology & Life Sciences
Healthcare
US
Needham
